Targeting HMGB1: An available Therapeutic Strategy for Breast Cancer Therapy
Open Access
- 1 January 2022
- journal article
- review article
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 18 (8) , 3421-3434
Abstract
HMGB1 is a member of highly conserved high mobility group protein superfamily with intracellular and extracellular distribution. Abnormal HMGB1 levels are frequently manifested in various malignant diseases, including breast cancer. Numerous studies have revealed the clinical value of HMGB1 in the diagnosis and therapy of breast cancer. However, the dual function of pro- and anti-tumor makes HMGB1 in cancer progression requires more profound understanding. This review summarizes the functions and mechanisms of HMGB1 on regulating breast cancer, including autophagy, immunogenic cell death, and interaction with the tumor microenvironment. These functions determine the strategies for the development of chemotherapy, radiotherapy, immunotherapy and combination therapies by targeting HMGB1 in breast cancer. Defining the mechanisms of HMGB1 on regulating breast cancer development and progression will facilitate the application of HMGB1 as a therapeutic target for breast cancer.Keywords
This publication has 116 references indexed in Scilit:
- p53-dependent release of Alarmin HMGB1 is a central mediator of senescent phenotypesJournal of Cell Biology, 2013
- Cooperative recruitment of HMGB1 during V(D)J recombination through interactions with RAG1 and DNANucleic Acids Research, 2013
- High-Mobility Group Boxes Mediate Cell Proliferation and Radiosensitivity via Retinoblastoma-Interaction-Dependent and -Independent MechanismsCancer Biotherapy and Radiopharmaceuticals, 2012
- High-Mobility Group Box 1 Is Essential for Mitochondrial Quality ControlCell Metabolism, 2011
- In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survivalThe Journal of Pathology, 2011
- Endogenous HMGB1 regulates autophagyJournal of Cell Biology, 2010
- HMGB1 release and redox regulates autophagy and apoptosis in cancer cellsOncogene, 2010
- HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase IINucleic Acids Research, 2009
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- TLR9 signals after translocating from the ER to CpG DNA in the lysosomeNature Immunology, 2004